How to use Ashwagandha in Parkinson's disease management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Incorporating Ashwagandha (Sastrivi) into Parkinson's Disease Management

Ashwagandha can be considered as an adjunctive neuroprotective agent in Parkinson's disease, but it must be carefully timed to avoid interfering with levodopa absorption, and should never replace standard dopaminergic therapy.

Critical Timing Considerations with Levodopa

The primary concern when adding ashwagandha to a Parkinson's regimen is avoiding interference with levodopa absorption:

  • Administer ashwagandha at least 2 hours separated from levodopa doses to prevent potential protein-based competition for absorption, similar to dietary protein interactions 1, 2.

  • Levodopa must be taken at least 30 minutes before meals to maximize absorption, as it competes with dietary large neutral amino acids for intestinal absorption and blood-brain barrier transport 3, 1, 2.

  • If the patient is on a protein redistribution diet (low-protein breakfast and lunch, normal protein at dinner), schedule ashwagandha with the evening meal when protein intake is higher 3, 2.

Evidence-Based Rationale for Ashwagandha Use

Ashwagandha demonstrates multiple neuroprotective mechanisms relevant to Parkinson's disease:

  • Combined treatment with ashwagandha and coenzyme-Q10 preserved neuron morphology in the substantia nigra and prevented motor impairment in paraquat-induced PD rat models 4.

  • Ashwagandha exhibits anti-inflammatory effects by inhibiting pro-inflammatory microglia while activating pro-survival astroglia 4.

  • The herb reduces oxidative stress and manages mitochondrial dysfunction, both key pathogenic mechanisms in Parkinson's disease 5, 4.

  • Ashwagandha may help manage α-synuclein aggregation and decrease pro-inflammatory cytokines, addressing core pathological features of PD 5.

Practical Integration Algorithm

Step 1: Optimize Standard Therapy First

  • Ensure levodopa timing is optimized (30 minutes before meals) 1, 2.
  • Implement protein redistribution if patient has motor fluctuations (0.8-1.0 g/kg body weight daily, concentrated at dinner) 1, 2.

Step 2: Add Ashwagandha Strategically

  • Start ashwagandha with the evening meal when protein intake is highest 3, 2.
  • Maintain at least 2-hour separation from any levodopa dose 1.
  • Consider combining with coenzyme-Q10 for synergistic neuroprotective effects 4.

Step 3: Monitor for Complications

  • Track motor symptoms to ensure ashwagandha doesn't interfere with levodopa efficacy 2, 6.
  • Monitor nutritional status including weight, vitamin B12, folate, and homocysteine levels, as levodopa increases these risks 1, 2.
  • Assess for gastrointestinal dysfunction that could impair levodopa bioavailability 1.

Critical Pitfalls to Avoid

  • Never use ashwagandha as monotherapy or suggest it can replace dopaminergic medications—levodopa remains the most effective treatment for PD 2, 6.

  • Avoid taking ashwagandha close to levodopa doses, as any protein or amino acid content could compete for absorption 3.

  • Do not create overly complex medication schedules that reduce adherence—simplicity improves compliance 1.

  • Recognize that ashwagandha provides neuroprotective effects but not immediate symptomatic relief like dopaminergic medications do 5, 4.

Monitoring Parameters

  • Motor function assessment including tremor, rigidity, bradykinesia, and duration of "ON" versus "OFF" states 2, 6.

  • Nutritional markers including body weight (weight loss associated with disease progression), vitamin D, B12, and folate levels 1, 2.

  • Homocysteine levels particularly in patients on higher levodopa doses, as levodopa methylation elevates homocysteine 1, 2.

  • Gastrointestinal symptoms including nausea, vomiting, constipation, and anorexia that may affect medication absorption 1, 2.

References

Guideline

Carbidopa and Levodopa in Parkinson's Disease Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment Regimen for Parkinson's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.